<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436578</url>
  </required_header>
  <id_info>
    <org_study_id>P08547</org_study_id>
    <secondary_id>MK-5592-091</secondary_id>
    <nct_id>NCT01436578</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Posaconazole Oral Suspension in Usual Practice in Korea (P08547)</brief_title>
  <official_title>Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of NOXAFIL Oral Suspension in Usual Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and efficacy of posaconazole in general use in Korea.

      Post-marketing surveys are not considered applicable clinical trials and thus the results of
      this survey will not be posted at its conclusion. The results will be submitted to public
      health officials as required by applicable national and international laws.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Serious Adverse Experiences</measure>
    <time_frame>During treatment and for 30 days following cessation of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with drug-related adverse experiences</measure>
    <time_frame>During treatment and for 30 days following cessation of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with unexpected drug-related adverse experiences</measure>
    <time_frame>During treatment and for 30 days following cessation of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Non-Serious Adverse Experiences</measure>
    <time_frame>During treatment and for 30 days following cessation of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Responses of Improved, Not Improved, and Worsened</measure>
    <time_frame>After at least 14 days of treatment</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">273</enrollment>
  <condition>Fungal Infections</condition>
  <arm_group>
    <arm_group_label>All Participants</arm_group_label>
    <description>All participants treated with posaconazole oral suspension during the pre-specified surveillance period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole oral suspension 40 mg/mL</intervention_name>
    <description>Posaconazole oral suspension prescribed according to the current local label</description>
    <arm_group_label>All Participants</arm_group_label>
    <other_name>NOXAFIL</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants enrolled will be all who are treated with posaconazole oral suspension per the
        current local label by participating investigators during the pre-specified surveillance
        period.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treated with posaconazole oral suspension within current local label

        Exclusion Criteria:

          -  Contraindication to posaconazole oral suspension according to current local label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <last_update_submitted>July 6, 2015</last_update_submitted>
  <last_update_submitted_qc>July 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

